Protein Kinase Inhibitors: all 15,766 studies that test it

Page 143 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid TumorsCompletedNCT00783328Phase 1
• Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)CompletedNCT00781846Phase 1
• Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver DiseaseCompletedNCT00781430Phase 1
• Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal CancerCompletedNCT00780169Phase 1
• Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled TrialCompletedNCT00779493Phase 4
• Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)TerminatedNCT00779480Phase 1
• Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC FamilyCompletedNCT00779389Phase 1
• Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)CompletedNCT00777959Phase 2
• Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid TumorsCompletedNCT00777699Phase 1
• Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy SubjectsCompletedNCT00777530Phase 1
• A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00777309Phase 2
• Study of Single Agent Perifosine for Recurrent Pediatric Solid TumorsCompletedNCT00776867Phase 1
• Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid MalignanciesTerminatedNCT00776373Phase 1/2
• Adjuvant Pazopanib in Stage I NSCLCCompletedNCT00775307Phase 2/3
• Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001CompletedNCT00775073Phase 2
• Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced CancerCompletedNCT00773929Phase 1
• A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.CompletedNCT00773526Phase 1
• A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory MalignanciesCompletedNCT00772876Phase 1
• Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to ChemotherapyStatus unknownNCT00772694Phase 2
• Relative Bioavailability of Phase II and Phase III Formulations of AZD0530CompletedNCT00771979Phase 1
• Study of Temsirolimus, Topotecan, and BortezomibCompletedNCT00770731Phase 1
• Erlotinib and Temsirolimus for Solid TumorsCompletedNCT00770263Phase 1
• Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial CancerCompletedNCT00770185Phase 2
• Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone MetastasesWithdrawnNCT00769990Phase 1/2
• Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
• Sorafenib and Transarterial Chemoembolization for Hepatocellular CarcinomaCompletedNCT00768937Phase 1/2
• CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma MultiformeStatus unknownNCT00768911Phase 1
• Safety of Immunosuppression Minimization in Children and Adolescents After Kidney TransplantationCompletedNCT00768729Phase 1
• Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and CirrhosisTerminatedNCT00767468Phase 1
• Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular DegenerationTerminatedNCT00766337Phase 2
• PHA-739358 for Treatment of Hormone Refractory Prostate CancerCompletedNCT00766324Phase 2
• Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast CancerStatus unknownNCT00764972Phase 1/2
• Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal TumorCompletedNCT00764595Phase 2
• Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2
• Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid LeukemiaCompletedNCT00762632Phase 1/2
• Signaling Mechanisms and Vascular Function in Diabetes MellitusCompletedNCT00761852Phase 2/3
• Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00761709Phase 2
• Doxil, Bevacizumab and Temsirolimus TrialCompletedNCT00761644Phase 1
• A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host DiseaseCompletedNCT00760981Phase 1
• PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid TumorsCompletedNCT00759928Phase 1
• Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsCompletedNCT00759837Phase 1
• Metastatic Advanced Pancreas SorafenibStatus unknownNCT00758381Phase 2
• Study Evaluating The Tolerability Of Multiple Doses Of HKI-272CompletedNCT00757809Phase 1
• Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.CompletedNCT00757692Phase 2
• Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606CompletedNCT00757341Phase 1
• Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsCompletedNCT00756847Phase 1
• A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid TumorsCompletedNCT00756340Phase 1
• Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast CancerTerminatedNCT00754702Phase 2
• Study of ABT-869 in Combination With Tarceva in Subjects With Solid TumorsWithdrawnNCT00754104Phase 1
• Sunitinib and Radiation in Patients With Resectable Soft-tissue SarcomaStatus unknownNCT00753727Phase 1/2
• Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus ErythematosusWithdrawnNCT00752999Phase 2
• Curcumin in Rheumatoid ArthritisCompletedNCT00752154Early Phase 1
• Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular CarcinomaStatus unknownNCT00752063Phase 2
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive, not recruitingNCT00750841Phase 1
• Nilotinib Pre and Post Allogeneic Stem Cell TransplantationCompletedNCT00750659Phase 2
• Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid TumoursCompletedNCT00750425Phase 1
• Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung CancerTerminatedNCT00749567Phase 2
• Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical TherapyCompletedNCT00749138Phase 1
• DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)CompletedNCT00748891Phase 1
• An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate CancerCompletedNCT00748358Phase 2
• Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)CompletedNCT00747799Phase 2
• Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By SurgeryTerminatedNCT00747305Phase 1
• Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00745732Phase 1
• A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisCompletedNCT00745550Phase 1/2
• Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)CompletedNCT00744081Phase 2
• A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedNCT00743938Phase 2
• A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid TumorsCompletedNCT00743067Phase 1
• A Bioavailability Study of GSK1363089 in Subjects With Solid TumorsCompletedNCT00742261Phase 1
• A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid TumorsCompletedNCT00742131Phase 1
• Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in JapanTerminatedNCT00742105Phase 1
• Extension Study of Semapimod 60 mg IV x 3 DaysCompletedNCT00741910Phase 2
• A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT00741871Phase 1
• Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's DiseaseCompletedNCT00740103Phase 2
• Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus PlaceboCompletedNCT00739986Phase 2
• Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)CompletedNCT00739830Phase 2
• A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)CompletedNCT00739453Phase 1
• Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersCompletedNCT00738751Phase 1
• Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain MetastasesWithdrawnNCT00738335Phase 1
• Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)CompletedNCT00736970Phase 2
• Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
• Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00734890Phase 1
• Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaTerminatedNCT00734526Phase 1
• Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869CompletedNCT00733187Phase 1
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918TerminatedNCT00733031Phase 1
• Sequential Study to Treat Renal Cell CarcinomaCompletedNCT00732914Phase 3
• Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy VolunteersCompletedNCT00732888Phase 1
• SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)CompletedNCT00732810Phase 2
• Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy VolunteersCompletedNCT00732784Phase 1
• Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00732745Phase 1
• Open-label Study of Topotecan and Pazopanib in Advanced Solid TumorsCompletedNCT00732420Phase 1
• Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid TumorsCompletedNCT00731861Phase 1
• A Study of Tor Kinase Inhibitor in Advanced TumorsCompletedNCT00731263Phase 1
• Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid TumorsCompletedNCT00730821Phase 1
• A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)CompletedNCT00730379Phase 1
• Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)CompletedNCT00729742Phase 1
• RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaCompletedNCT00729638Phase 1
• A Study of ARRY-371797 in Patients With Rheumatoid ArthritisCompletedNCT00729209Phase 1
• A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid TumorsCompletedNCT00728793Phase 1
• A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 WeeksCompletedNCT00728390Phase 1
• Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic AdenocarcinomaWithdrawnNCT00728000Phase 2

← Protein Kinase Inhibitors overview